



The Illinois Medical Bulletin



The Role of Statin Therapy in the Primary Prevention of Cardiovascular Events: A Review of Pivotal Trial Evidence

¹A. Chamberlain, ²A. Cher

^{1,2} University of Illinois College of Medicine

Corresponding Email : chamberlain284883@gmail.com

Article History :

Received date : 2020/10/12
Revised date : 2020/11/28
Accepted date : 2020/12/09
Published date : 2021/01/13



Copyright: © by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) license (<https://creativecommons.org/licenses/by-nc/4.0/>).

ABSTRACT

Introduction: Atherosclerotic cardiovascular disease is a leading cause of global mortality. While the efficacy of statin therapy for secondary prevention in patients with established disease was well-accepted, its role in primary prevention for individuals without prior cardiovascular events was a critical area of clinical investigation.

Literature Review: A review of pivotal randomized trials reveals the progressive confirmation of statin efficacy in primary prevention. Landmark studies demonstrated a significant reduction in major cardiovascular events in key high-risk populations, including individuals with hypertension and those with type 2 diabetes. Large-scale meta-analyses further substantiated the benefit of LDL cholesterol lowering across a broad spectrum of baseline risk. The paradigm was further expanded by a groundbreaking trial which showed that statin therapy was highly effective in individuals with low or normal cholesterol levels but with evidence of systemic inflammation, as indicated by elevated high-sensitivity C-reactive protein. This established that cardiovascular benefit extended beyond lipid levels alone.

Conclusion: This body of evidence firmly established statin therapy as a cornerstone of primary cardiovascular prevention. The findings broadened the indications for treatment to a wide range of at-risk individuals, confirming the benefit of lowering LDL cholesterol and introducing the concept of treating inflammation to prevent first-time cardiovascular events.

Keywords: Statins, Primary Prevention, Cardiovascular Disease, Cholesterol, LDL Cholesterol, Inflammation.

INTRODUCTION

Atherosclerotic cardiovascular disease (ASCVD), encompassing events such as myocardial infarction and ischemic stroke, represents a paramount public health challenge. A central strategy in mitigating its impact is primary prevention—intervening to prevent a first cardiovascular event in individuals who are at risk but have not yet developed clinical disease. HMG-CoA reductase inhibitors, or statins, emerged as the most powerful class of drugs for lowering low-density lipoprotein (LDL) cholesterol, a primary causal factor in atherosclerosis.

While the profound benefits of statins in secondary prevention were unequivocally established, their precise role and the extent of their benefit in primary prevention were subjects of intense and ongoing investigation. The core question was to define which at-risk populations without established ASCVD stood to gain a clear net benefit from long-term statin therapy. This literature review will synthesise the pivotal clinical trial evidence that solidified the role of statins as a fundamental strategy in the primary prevention of cardiovascular disease.

LITERATURE REVIEW

The evidence supporting statin use for primary prevention was built progressively through a series of large-scale, randomized controlled trials that targeted different at-risk populations.

A key population of interest was patients with hypertension, a major risk factor for ASCVD. The Anglo-Scandinavian Cardiac Outcomes Trial–Lipid-Lowering Arm (ASCOT-LLA) was a landmark study that addressed this group. It enrolled hypertensive patients with at least three other cardiovascular risk factors but no history of coronary heart disease. The trial was stopped prematurely due to the clear evidence of benefit, with atorvastatin showing a significant reduction in the primary endpoint of nonfatal myocardial infarction and fatal coronary heart

disease (Sever et al., 2003). This provided robust evidence that treating lipids in hypertensive patients conferred benefits beyond blood pressure control alone.

Another critical group at high cardiovascular risk is patients with type 2 diabetes. The Collaborative Atorvastatin Diabetes Study (CARDS) was designed specifically to evaluate the efficacy of statin therapy in this primary prevention population. The trial enrolled diabetic patients without known vascular disease and, like ASCOT-LLA, was stopped early on the recommendation of its data monitoring committee. The results showed that atorvastatin produced a substantial and highly significant reduction in major cardiovascular events, including strokes (Colhoun et al., 2004). This trial provided definitive evidence supporting the routine use of statins in patients with type 2 diabetes for primary prevention.

The accumulating data from these and other trials were synthesised in large meta-analyses, which provided overarching insights. The Cholesterol Treatment Trialists' (CTT) Collaborators published an influential analysis of data from numerous trials involving tens of thousands of patients. Their findings demonstrated a consistent proportional reduction in major vascular events for every unit reduction in LDL cholesterol, a benefit that was present across a wide range of baseline risks, including in populations without prior vascular disease (Cholesterol Treatment Trialists' (CTT) Collaborators, 2005). This strongly supported the "lower is better" concept for LDL cholesterol, even in primary prevention.

Perhaps the most paradigm-shifting development was the investigation of statin benefit in a population not defined by high cholesterol. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) tested a novel hypothesis based on the role of inflammation in atherosclerosis. It enrolled individuals who had low-to-normal LDL cholesterol levels but elevated levels of high-sensitivity C-reactive protein (hs-CRP), a marker of inflammation. The results were dramatic: rosuvastatin significantly reduced the incidence of major cardiovascular events by nearly half (Ridker et al., 2008). This landmark study proved that individuals could benefit from statin therapy even without hyperlipidemia if significant underlying inflammation was present, thus expanding the scope of primary prevention beyond a purely lipid-centric approach.

CONCLUSION

The pivotal body of clinical trial evidence examining statin therapy for primary prevention fundamentally reshaped modern cardiovascular medicine. It moved the use of statins from a niche secondary prevention strategy to a cornerstone of public health for at-risk populations. Landmark trials provided definitive proof of efficacy in preventing first-time cardiovascular events in individuals with common risk factors such as hypertension and type 2 diabetes.

Furthermore, large-scale meta-analyses confirmed a consistent benefit of LDL cholesterol lowering across a broad spectrum of risk, while the novel approach of targeting inflammation identified a new population that stands to benefit from treatment. This collective evidence solidified the central role of statins in the primary prevention of atherosclerotic cardiovascular disease, providing a robust, evidence-based foundation for current clinical guidelines.

REFERENCES

Cholesterol Treatment Trialists' (CTT) Collaborators. (2005) 'Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins', *The Lancet*, 366(9493), pp. 1267-1278.

Colhoun, H.M., Betteridge, D.J., Durrington, P.N., Hitman, G.A., Neil, H.A., Livingstone, S.J., Thomason, M.J., Mackness, M.I., Charlton-Menys, V. and Fuller, J.H. (2004) 'Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial', *The Lancet*, 364(9435), pp. 685-696.

Ridker, P.M., Danielson, E., Fonseca, F.A., Genest, J., Gotto, A.M., Jr., Kastelein, J.J., Koenig, W., Libby, P., Lorenzatti, A.J., MacFadyen, J.G., Nordestgaard, B.G., Shepherd, J., Willerson, J.T. and Glynn, R.J. (2008) 'Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein', *New England Journal of Medicine*, 359(21), pp. 2195-2207.

Sever, P.S., Dahlöf, B., Poulter, N.R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S.E., Kristinsson, A., McInnes, G.T., Mehlsen, J., Nieminen, M., O'Brien, E. and Ostergren, J. (2003) 'Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial', *The Lancet*, 361(9364), pp. 1149-1158.

The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. (2002) 'Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)', *JAMA*, 288(23), pp. 2998-3007.